...
首页> 外文期刊>Frontiers in Veterinary Science >Cellular distribution of canonical and putative cannabinoid receptors in canine cervical dorsal root ganglia
【24h】

Cellular distribution of canonical and putative cannabinoid receptors in canine cervical dorsal root ganglia

机译:犬颈背根神经节中典型和假定大麻素受体的细胞分布

获取原文

摘要

Growing evidence indicates cannabinoid receptors as potential therapeutic targets for chronic pain. Consequently, cannabinoid receptor agonists might have a role in medicine and are now being developed to be used in human and veterinary patients in pain. To better understand the actions of a drug, it is of paramount importance to know the cellular distribution of its specific receptor(s). The distribution of canonical and putative cannabinoid receptors in the peripheral and central nervous system of dogs is still in its infancy. In order to help fill this anatomical gap, the present ex vivo study has been designed to identify the cellular sites of cannabinoid and cannabinoid-related receptors in canine spinal ganglia. In particular, the cellular distribution of the cannabinoid receptors type 1 and 2 (CB1 and CB2) and putative cannabinoid receptors G protein-coupled receptor 55 (GPR55), nuclear peroxisome proliferator-activated receptor alpha (PPARα), and transient receptor potential vanilloid type 1 (TRPV1) have been immunohistochemically investigated in the C6-C8 cervical ganglia of dogs. Faint CB1 receptor immunoreactivity was observed in small-sized neurons, whereas Schwann cells, blood vessel smooth muscle cells, and pericyte-like cells brightly expressed CB2 receptor immunoreactivity. Bright GPR55 receptor immunoreactivity was expressed by satellite glial cells (SGCs) whereas neurons of different size showed faint to moderate immunolabeling. PPARα immunoreactivity was expressed by SGCs and endothelial blood vessels. TRPV1 immunoreactivity was expressed by neurons and nerve fibers of different size. The present study may represent a morphological substrate to consider in order to develop therapeutic strategies against chronic pain.
机译:越来越多的证据表明,大麻素受体可作为慢性疼痛的潜在治疗靶标。因此,大麻素受体激动剂可能会在医学上发挥作用,目前正在开发中,以用于痛苦中的人类和兽医患者。为了更好地理解药物的作用,了解其特定受体的细胞分布至关重要。犬的外周和中枢神经系统中规范性和推定性大麻素受体的分布仍处于婴儿期。为了帮助填补这一解剖学空白,已设计了本离体研究以鉴定犬脊柱神经节中大麻素和大麻素相关受体的细胞部位。特别是1型和2型大麻素受体(CB1和CB2)和假定的大麻素受体G蛋白偶联受体55(GPR55),核过氧化物酶体增殖物激活的受体α(PPARα)和瞬时受体电位类香草素的细胞分布1(TRPV1)已在犬的C6-C8颈神经节中进行了免疫组织化学研究。在小型神经元中观察到微弱的CB1受体免疫反应性,而Schwann细胞,血管平滑肌细胞和周细胞样细胞明亮地表达CB2受体免疫反应性。卫星神经胶质细胞(SGC)表达了明亮的GPR55受体免疫反应性,而不同大小的神经元则显示了微弱至中等的免疫标记。 PPARα免疫反应性由SGC和内皮血管表达。 TRPV1免疫反应性由不同大小的神经元和神经纤维表达。本研究可能代表要发展针对慢性疼痛的治疗策略要考虑的形态底物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号